NCT04187404

A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma

A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 70 (actual)
• Sponsor: Enterome · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.

Detailed description

EO2401 is an innovative cancer peptide therapeutic vaccine based on the homologies between Tumor Associated Antigens and microbiome-derived peptides that will be administered in combination with nivolumab to generate preliminary safety and efficacy data in patients with Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.

Conditions

• Adrenocortical Carcinoma
• Pheochromocytoma
• Paraganglioma

Interventions

Type	Name	Description
BIOLOGICAL	EO2401	Multiple dose of EO2401
BIOLOGICAL	Nivolumab	Multiple dose of nivolumab

Timeline

• Start date: 2020-07-23
• Primary completion: 2024-10-02
• Completion: 2024-10-02
• First posted: 2019-12-05
• Last updated: 2026-01-30
• Results posted: 2026-01-30

Locations

12 sites across 8 countries: United States, Denmark, France, Germany, Italy, Netherlands, Spain, Sweden

Regulatory

• FDA-regulated drug study